F-star Biotechnology Ltd has appointed Neil Brewis, the former head of biopharmaceutical research at GlaxoSmithKline Plc, as its chief scientific officer.
The Cambridge, UK-based company specialises in developing bispecific antibodies that bind to two different targets concurrently. Its lead product targets HER2-positive cancers and is partnered with Bristol Myers Squibb Corporation.
At GSK, Dr Brewis led a team of scientists who advanced monoclonal antibodies, antibody fragments and protein therapeutics from target validation to early clinical development. Prior to this, he was head of research at Domantis Ltd, an antibody company acquired by GSK in 2007. Dr Brewis has a PhD in biochemistry from the University of Dundee in the UK.
F-star announced the appointment on 2 November 2015.
Copyright 2015 Evernow Publishing Ltd